Jean‐Louis Abitbol

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH

Sven Francque, Pierre Bédossa, Vlad Ratziu et al. · New England Journal of Medicine · 2021 · 721 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

Michel Delvaux, Dominique Louvel, E. Lagier et al. · Gastroenterology · 1999 · 154 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome

Michel Dapoigny, Jean‐Louis Abitbol, B Fraitag · Digestive Diseases and Sciences · 1995 · 153 citations

Medicine, Pharmacology, Pharmacotherapy +11

A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis

Timothée Lenglet, Lucette Lacomblez, Jean‐Louis Abitbol et al. · European Journal of Neurology · 2014 · 128 citations

Medicine, Neurology, Pharmacotherapy +17

Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial

Enrico Bertini, Éric Dessaud, Eugenio Mercuri et al. · The Lancet Neurology · 2017 · 114 citations · Full text

Medicine, Pharmacotherapy, Clinical Pharmacology +4